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Abstract
Background: Human immunodeficiency virus (HIV)-1-associated neurocognitive disorders (HAND) are characterized by
synaptic damage and neuronal loss in the brain. Excessive glutamatergic transmission and loss of cholinergic neurons
are the major indicators of HAND. Nicotine acts as a cholinergic channel modulator, and its cognitive-enhancing effect
in neurodegenerative and cognitive disorders has been documented. However, it is unclear whether nicotine has any
positive effect on memory and synaptic plasticity formation in HAND.
Methods: We investigated the effects of nicotine on synaptic plasticity and hippocampus–prefrontal cortex
(PFC)–amygdala-dependent memory formation in the HIV-1 transgenic (Tg) and F344 control rats.
Results: Chronic nicotine treatment (0.4 mg/kg nicotine, base, subcutaneously) significantly attenuated the
cognitive deficits in the HIV-1Tg rats in both the spatial and contextual fear memories but impaired the
contextual learning memory in the F344 rats. To determine the role of nicotine in the synaptic dysfunction
caused by HIV-1 proteins, we analyzed the expression of key representative genes related to synaptic plasticity in
the hippocampus, PFC, and amygdala of the HIV-1Tg and F344 rats using a custom-designed qRT-PCR array. The
HIV-1 proteins significantly altered the glutamate receptor-mediated intracellular calcium cascade and its
downstream signaling cascade in a brain region-specific manner. Further, chronic nicotine treatment reversed the
effect of HIV-1 proteins on the expression of genes involved in synaptic plasticity in the three brain regions. The
effects of nicotine differed significantly in the HIV-1Tg and F344 rats.
Conclusions: Our findings indicate that nicotine can attenuate the effect of HIV viral proteins on cognitive
function and produce a brain region- and strain-specific effect on the intracellular signaling cascades involved in
synaptic plasticity and memory formation.
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Introduction
Human immunodeficiency virus (HIV)-1 proteins pene-
trate the central nervous system (CNS) during the early
stages of viral infection and induce progressive neuronal
damages in the brain [1, 2]. HIV-1-associated neurocog-
nitive disorders (HAND) are the major CNS complica-
tions of HIV-1 infection, with approximately 50 % of
patients developing some degrees of cognitive impair-
ment [3]. Working (short-term) and episodic memory
(involving short-term and long-term memory) impair-
ments are the most commonly observed cognitive defi-
cits in the HAND patients [3–5]. Recent studies have
revealed that progression of HAND is accelerated by
drug abuse in the HIV-1-infected patients. Cigarette
smoking has a high prevalence in the HIV population,
which abuses multiple drugs [6, 7]. It has been reasoned
that the high prevalence of smoking in HIV-1-infected
patients is attributable to the compensatory effect of
smoking on cognitive deficits [7].
Nicotine is the main psychoactive component of
cigarette smoke, and it has variable effects on cognitive
function. There has been relatively little research on the
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relation between nicotine and progression of HAND.
Recently, Wojna et al. [8] reported that HIV-1-infected
smokers exhibited less cognitive impairment than in-
fected non-smokers. Studies of animal models of HIV-1
infection demonstrate that chronic nicotine treatment re-
stored the effect induced by viral proteins on the multiple
intracellular signaling pathways in the different brain re-
gions of the HIV-1Tg rats [9]. However, nicotine-induced
molecular alterations in the neural circuits of working and
episodic memory have not been fully elucidated in the
presence of HIV-1 viral proteins.
Memory formation depends on the activity of intercon-
nected neurons through synapses within the hippocam-
pus, prefrontal cortex (PFC), and amygdala [10]. The
dynamic interaction between glutamatergic and choliner-
gic synapses has a major role in encoding of new informa-
tion into short-term and long-term memories [11, 12].
Dysfunction in the brain glutamatergic and cholinergic
neurotransmission is postulated to be one of the con-
tributors to memory impairment during HIV-1 infection
[13, 14]. The effects of HIV-1 proteins on the gluta-
matergic neurotransmission system have been investigated
[15, 16]. Results from these studies show that HIV viral
proteins induce excessive glutamate release from in-
fected microglia cells and result in glutamate-mediated
neurotoxicity in the cortical and subcortical regions of
the brain [16]. Further, mechanistic studies of HIV-1 in-
fection have demonstrated that viral proteins lead to
glutamate-induced deregulation of calcium homeostasis
by overactivating N-Methyl-D-aspartic acid (NMDA)
and metabotropic glutamate receptors (mGluRs). Acti-
vation of these receptors enhances subsequent calcium-
mediated apoptosis signaling in the neurons [13, 17, 18]. Re-
cent studies also showed that brain cholinergic neurons
are affected by HIV viral proteins [13, 14]. Depboylu et
al. [19] reported that chronic inflammation acted as a
key mediator of HIV-1 protein-induced cholinergic dys-
function and neuronal loss in the brain that contributes
to learning and memory impairment.
Stimulation of the cholinergic system by nicotinic
acetylcholine receptor (nAChR) agonists protects against
glutamate-mediated neurotoxicity and leads to subse-
quent cognitive improvement in rodent models of neu-
rodegenerative disorders [20]. A low dose of nicotine
enhances cognitive performance by attenuating the im-
pairment of cholinergic neurotransmission [21, 22]. Ex-
perimental treatment of neurodegenerative disorders
shows that nicotine mediates neuroprotection against
NMDA-mediated excitotoxicity in the neurons by
calcium-dependent mechanisms via neuronal α4β2- and
α7-containing nAChRs [23–26]. These results indicate
that nicotine has a modulatory effect on the neuronal
circuitry of learning and memory during glutamate-
mediated excitotoxicity and neurodegeneration.
The main goal of the current study was to determine
how nicotine induces behavioral and molecular alterations
in cognitive-impaired HIV-1Tg rats. From these experi-
ments, we aimed to answer the following two interrelated
questions: (1) does chronic nicotine treatment attenuate
HIV-1-associated cognitive impairment? And (2) does nico-
tine show differential effects on intracellular signaling
mechanisms underlying the synaptic plasticity formation of
the HIV-1Tg rats in comparison to the F344 control ani-
mals? We addressed the first question by testing HIV-1Tg
and F344 rats for spatial working memory in the Y-maze
and then for contextual fear memory in the passive avoid-
ance test. We then answered the question further by ana-
lyzing the transcription of genes involved in synaptic
plasticity in the hippocampus, PFC, and amygdala of the
same set of rats.
Materials and methods
Animals
Male HIV-1Tg and F344 genetic background control rats
(Harlan Industries, USA) at 7 to 8 weeks of age were
used. Rats were housed two per cage in a temperature
(20 °C–22 °C)- and humidity (45 %–55 %)-controlled en-
vironment on a 12-h light/dark cycle. Food and water
were provided ad libitum. All behavioral experiments
were conducted between 9:00 AM and 1:00 PM and were
in accordance with the guideline of the University of
Virginia Animal Research Committee.
Drugs and treatment
Rats from each strain were divided randomly into two
groups: saline-treated control and nicotine treated, des-
ignated as follows: F344_Saline (n = 11); F344_Nicotine
(n = 12); HIV-1Tg_Saline (n = 9); HIV-1Tg_Nicotine (n =
11). To determine the effects of chronic nicotine treat-
ment on spatial working and contextual memory, F344
and HIV-1Tg rats received a single subcutaneous injec-
tion of either saline or nicotine at a dose of 0.4 mg/kg/
day (nicotine free base) for 15 days before starting the
behavioral experiments.
(−)–Nicotine hydrogen tartrate (Sigma, St. Louis, MO)
was dissolved in 0.9 % physiological saline, and its con-
centration was calculated as nicotine free base. On day
15, rats were tested for their spatial working memory in
the Y-maze with the spontaneous alternation behavioral
paradigm. Contextual fear memory experiments were
conducted 1 week after the spontaneous alternation be-
havior test. Between days 22 and 26, rats were tested for
short- and long-term contextual fear memory perform-
ance in the passive avoidance box with the one-step-
through passive avoidance protocol. All rats received
their last nicotine or saline injection on day 27 and were
decapitated within 24 h after the last injection. Because
of congenital cataracts of the HIV-1Tg rats, all behavioral
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experiments were conducted under dimmed red light to
minimize the visual differences between the strains.
Y–maze task test
Spatial working memory performance of HIV-1Tg and
F344 rats was assessed by recording spontaneous alter-
nation behavior during an 8-min session in the Y-maze
test apparatus according to published protocols [27, 28].
The Y-maze has three arms, each 45 cm long, 10 cm
wide, and 35 cm high. The arms were positioned at
equal angles and converged in an equilateral triangular
central area. Each rat was placed at the end of an arm
and allowed to move freely through the Y-maze without
reinforcements such as food, water, or electric shock.
The series of arm entries was recorded by the Any-Maze
video tracking system (Stoelting Co., Wood Dale, IL,
USA). An arm entry was said to be complete when all
four paws of the subject had been placed in the arm. Al-
ternation behavior (actual alternations) was defined as
successive entries into the three arms with overlapping
triplet sets. The percent alternation was calculated as
the ratio of actual alternation to possible alternations
(total number of arm entries – 2) × 100.
Passive avoidance test
The multiple trial one-step-through passive avoidance ex-
periments were carried out between Days 22 and 26 with
the goals of testing acquisition and short- and long-term
contextual memory. The passive avoidance apparatus
(Coulbourn Instruments Inc. Whitehall, PA, USA) con-
sists of two compartments (illuminated and darkened)
both equipped with a grid floor. The two compartments
are separated by an automatic guillotine door.
The one-step-through passive avoidance experiment
consisted of a single training and multiple testing ses-
sions. On Day 24, each rat was placed in the illuminated
chamber. After the placement, each rat explored the two
compartments freely for 5 min. During the training ses-
sion on Day 25, the rat was placed in the illuminated
compartment for 15 s before the door was raised. After
the rat entered the darkened compartment, the door was
closed, and an electrical foot shock was delivered at
0.4 mA for 2 s. The subject was removed 30 s after re-
ceiving the foot shock and returned to its home cage.
During the training session, retention latency for enter-
ing the dark compartment was recorded.
The test trials were conducted at the intervals of 1, 24,
48, and 72 h after the training session. During the test
sessions, the rat was placed in the illuminated compart-
ment, with the guillotine door closed for 30 s. After that,
the door was opened, and retention latency for entering
the dark compartment and the time spent in both com-
partments were recorded for 300 s, at which the time,
the test was terminated. No electric shock was delivered
during the test trials.
Tissue collection
The animals were sacrificed and decapitated 1 day after
the last nicotine injection, and their brains were immedi-
ately isolated. Tissues were collected from the hippocam-
pus, PFC, and amygdala according to the rat brain atlas
[29]. By using a rat brain matrix, slices of approximately
1.0 mm were taken from each brain, and tissues from the
specific regions of interest were collected bilaterally from
each slice with a 3.00-mm Harris Micro-Punch (GE
Healthcare Life Sciences, Piscataway, NJ, USA). All
punched tissue samples were stored at −80 °C until use.
Quantitative RT-PCR (qRT-PCR) array
We used a custom-designed pathway-focused RT-PCR
array with the goal of determining the RNA expression of
genes involved in synaptic plasticity. By using the Ingenu-
ity Pathway Analysis (IPA) software (http://ingenuity.com)
to search the Kyoto Encyclopedia of Genes and Genome
Pathway database (www.genome.jp/kegg/), we selected 80
genes related to synaptic plasticity formation for this
custom-designed array. These genes can be grouped into
the following biological processes: long-term potentiation
(46 genes), long-term depression (25 genes), immediate
early gene response (16 genes), cell adhesion (9 genes),
extracellular matrix and proteolytic processing (2 genes),
Creb signaling (20 genes), and postsynaptic density forma-
tion (16 genes).
The primers of each gene selected for the qRT-PCR
assay were designed with Primer Express (v. 3.0) soft-
ware (Applied Biosystems, Carlsbad, CA, USA) and
spanned at least one intron to avoid amplifying genomic
DNA. The primers had a melting temperature from
59 °C to 61 °C. Each pair of primers and their amplicon
sequences were tested using the Basic Local Alignment
SearchTool (BLAST; http://blast.ncbi.nlm.nih.gov/Blast.cgi)
to ensure the specificity of the designed primers for the tar-
geted genes. Dissociation curves were generated to check
the specificity of the primers before including them in
the qRT-PCR array. All primer sequences are listed in
Additional file 1: Table S1.
Total RNA was isolated using the Trizol agent
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s protocol. The purity and quantity of total RNA
were measured at optical densities of 260 and 280 nm
with NanoDrop 2000c (Thermo Scientific, Waltham, MA,
USA). Two μg of total RNA was reverse-transcribed into
the first-strand cDNA using Superscript II reverse tran-
scriptase. The cDNA mixture was incubated at 25 °C for
10 min, 42 °C for 1.5 h, and 70 °C for 15 min. The PCR
amplification was conducted as described previously [30].
Briefly, the product was amplified in a volume of 10 μl
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containing 5.0 μl of 2× Power SYBR Green PCR Master
Mix (Applied Biosystems) and combined sense and anti-
sense primers (2.5 μl; final concentration 20 nM) in a 384-
well plate using the 7900HT Sequence Detection System
(Applied Biosystems). The PCR conditions were as fol-
lows: 95 °C for 10 min, followed by 40 cycles of 95 °C
for 15 s and 60 °C for 1 min. A cycle threshold was
assigned at the beginning of the logarithmic phase of
the amplification, and differences in the Ct values of the
control and nicotine-treated groups were used to deter-
mine the relative expression of genes of interest. Melt-
ing curve analysis was applied to characterize the
specificity of the amplifications.
Statistical analysis
Data are expressed as mean ± S.E.M. For the Y-maze ex-
periments, data were analyzed using one-way analysis of
variance (ANOVA) followed by post-hoc Bonferroni ana-
lysis. For the results of the passive avoidance test, data
were analyzed using the Kruskall-Wallis ANOVA by com-
paring mean ranks followed by nonparametric analysis
with the Mann–Whitney U test. The Kruskall Kruskall-
Wallis test is a nonparametric H test; therefore, the signifi-
cant result function definitions with this test are presented
as H instead of parametric test script F. Differences were
considered statistically significant at p < 0.05.
Expression of each gene of interest was first normal-
ized to the expression of the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and then analyzed using a comparative Ct method [31].
The relative expression of each gene was compared
within and between HIV-1 Tg and F344 rats using
the Student t-test. Significant alteration in mRNA
expression was defined as a fold change > 20 % with a
p value < 0.05 (N = 4–6 per group).
Results
Improvement of spatial working memory performance by
chronic nicotine treatment in the HIV-1Tg and F344 rats
To evaluate the effects of HIV viral proteins and nicotine
on spatial working memory performance, spontaneous
alternation behavior was tested in the nicotine-treated
and saline control groups of both HIV-1Tg and F344
rats. First, there was a significant group difference be-
tween the HIV-1Tg_Saline and F344_Saline groups (F
[3, 31] = 10.83; p < 0.05) (Fig. 1a). Post hoc analysis re-
vealed that the HIV-1Tg_Saline group showed a low fre-
quency of spontaneous alternation behavior compared
with the F344_Saline group (p < 0.01).
Chronic daily treatment with nicotine at a dose of
0.4 mg/kg for 15 days attenuated the viral protein-induced
spatial working memory deficit. Spontaneous alternation
behavior was significantly higher in the HIV-1Tg_Nicotine
group than in the HIV-1Tg_Saline group (p < 0.01). No
significant difference in the total number of arm entries
was detected between the nicotine and control groups of
either HIV-1Tg or F344 rats (Fig. 1b). These findings indi-
cate that changes in the alternation behavior in the HIV-
1Tg or F344 rats did not occur as a result of alterations in
nicotine-induced locomotor activity.
Chronic nicotine treatment enhanced the contextual
memory in HIV-1Tg rats but impaired performance in
F344 rats
The effect of HIV-1 proteins and chronic nicotine treat-
ment on the contextual memory performance was
a b
Fig. 1 Nicotine effects on spatial working memory. a Spontaneous alteration behavior. b Number of arm entries during an eight-min session in
the Y-maze task on day 15 (N = 9–12/group). Vertical bars show mean ± S.E.M. **, ++p < 0.01 compared with F344 saline-treated rats; #p < 0.01
compared with HIV-1Tg nicotine-treated rats
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assessed by the one-step-through passive avoidance test
in both rat strains. In the acquisition trial, we found no
significant difference between the nicotine- and saline-
treated groups of either F344 or HIV-1Tg rats (Fig. 2).
However, there was a significant strain difference in the
one-step-through latency in the 1, 24, 48, and 72 h re-
tention trials (H = 9.12, p < 0.05; H = 14.74, p < 0.01; H =
7.89, p < 0.05; H = 8.50, p < 0.05, respectively). Nicotine
prolonged the latency of entering the dark box in the
HIV-1Tg rats, but impaired the passive avoidance behav-
ior in F344 rats. Non-parametric analysis by the Mann–
Whitney U test revealed that the HIV-1Tg_Nicotine
group showed a significant increase in one-step-through
latency at 24, 48, and 72 h compared with their control
group (p < 0.05). In the F344 rats, chronic nicotine treat-
ment induced a significant reduction in the one-step-
through latency in the retention trials compared with
the control group (p < 0.05).
HIV-1 proteins altered the expression of synaptic
plasticity genes in a brain region-specific manner
To determine the effect of HIV-1 proteins on the ex-
pression of genes related to synaptic plasticity, we ana-
lyzed the expression of the 80 genes in the qRT-PCR
array. We found significant expression differences be-
tween the two strains on 16 genes in the hippocampus,
17 genes in the PFC, and 12 genes in the amygdala, re-
spectively, which were classified into six signaling path-
ways in the hippocampus and five in the PFC or
amygdala region of the HIV-1Tg_Saline group (Table 1).
The HIV-1 proteins altered the expression of genes en-
coding members of mGluR-mediated PLC/IP3-mediated
calcium signaling, with 36 %–78 % significant upregulation
of Grm 5, Plcb4, and ltpr3 in the hippocampus and 19 %–
30 % significant downregulation of Grm1, Plcb4, Itpr1, and
Itpr2 in the PFC (Table 1; Fig. 3a, b). In the voltage-
dependent Ca+ 2 channel (VDCC)-mediated calcium sig-
naling and Ca+2/calmodulin-dependent kinase signaling
pathways, viral proteins significantly upregulated the ex-
pression of Cacna1i, Calm4, and Camk4, by 20 %–50 %, in
the hippocampus but downregulated the expression of
Cacna1g and Camk2g by 68 % and 79 %, respectively, in
the PFC and of Cacna1g and Calm2 by 63 % and 71 %, re-
spectively, in the amygdala (Table 1). We did not observe
significant alterations in response to viral proteins in the
expression of genes involved in Creb signaling in the PFC
and amygdala, but there was significant upregulation
(43 %) of the expression of transcription factor Creb2 by
viral proteins in the hippocampus (Fig. 3a).
Expression of genes involved in the MAP kinase sig-
naling pathway and synapse formation was significantly
changed by viral proteins in all three brain regions. In
the MAP kinase pathway, viral proteins significantly de-
creased the expression of Mapk3, by 19 %, in the hippo-
campus; of Raf1, Map2k1, and Mapk3, by18 %–27 % in
the PFC; and of the same genes, by 27 %–31 % in the
amygdala. There was a significant decrease in the ex-
pression of genes associated with immediate early re-
sponse and postsynaptic density formation in the
hippocampus and amygdala (Table 1). Together, these
results indicate that HIV-1 proteins exert a brain region-
specific modulation of the expression of genes involved
in intracellular calcium signaling and calmodulin-
dependent kinase signaling pathways.
# # # #
Fig. 2 Effects of nicotine on step-through latency in the multiple-trial passive avoidance task on Days 22–26 in F344 and HIV-1Tg rats. Rats
received daily nicotine injections five-min before the behavioral test (N = 9–12/group). Data are shown as mean ± S.E.M of the one-step
through avoidance latencies at 1, 24, 48, and 72 h after the foot shock. *p < 0.05 in difference from F344-nicotine treated group; #p < 0.05 in
difference from HIV-1Tg saline-treated group (Mann–Whitney U-test)
Nesil et al. Molecular Brain  (2015) 8:43 Page 5 of 17
Table 1 HIV-1 viral proteins induced significant alterations in the expression of synaptic plasticity genes. A total of 80 synaptic
plasticity genes were analyzed using a qRT-PCR-array analysis. Among them, 50 showed significant strain-specific expression (p < 0.05
and fold change >20 %) in the hippocampus, prefrontal cortex, or amygdala














4.4E-02 ± 3.4E-03 6.0E-02 ± 2.1E-03 1.36 0.004
Plcb4 Phospholipase C activity 2.4E-02 ± 2.2E-04 3.9E-04 ± 3.8E-04 1.63 0.005
Itpr3 Calcium ion transmembrane
transporter activity





2.0E-03 ± 3.6E-04 3.0E-03 ± 2.1E-04 1.5 0.04
Camk4 Calmodulin dependent
protein kinase activity
3.3E-02 ± 1.1E-03 3.9E-02 ± 1.7E-03 1.2 0.02
Calm4 Calcium ion binding 2.6E-03 ± 3.1E-04 3.7E-03 ± 2.5E-04 1.42 0.03
CREB signaling Creb-2 (Atf4) Transcription
factor activity
8.0E-03 ± 2.8E-04 1.2E-02 ± 4.4E-04 1.57 0.01
Kinase signaling Akt1 (PKB) Protein kinase activity 2.7E-02 ± 2.4E-03 4.0E-02 ± 2.6E-03 1.48 0.006
Mapk3 Mitogen activated
kinase activity
9.6E-02 ± 8.0E-03 7.2E-02 ± 6.5E-03 0.74 0.03
Adcy8 Adenylate cyclase
activity
7.6E-03 ± 4.2E-04 6.1E-03 ± 6.0E-04 0.80 0.033
Immediate early response gene Arc Actin binding 1.2E-02 ± 2.0E-02 6.2E-03 ± 1.2E-03 0.49 0.03
Bdnf Growth factor activity 4.2E-04 ± 5.0E-05 2.3E-04 ± 7.1E-05 0.56 0.02
Jun-b Transcription factor
activity
1.5E-02 ± 2.2E-03 9.9E-03 ± 7.5E-04 0.63 0.03
Ngf Growth factor activity 6.5E-03 ± 4.7E-04 4.9E-03 ± 4.8E-04 0.75 0.01
Postsynaptic organization of synapse Gria1 Glutamate receptor activity 2.2E-01 ± 2.4E-02 1.5E-01 ± 1.7E-02 0.69 0.006







5.6E-02 ± 8.0E-03 3.3E-02 ± 5.5E-03 0.58 0.03
Plcb4 Phospholipase C activity 2.0E-02 ± 1.2E-04 1.4E-02 ± 5.8E-04 0.70 0.002
Itpr1 Calcium Ion transmembrane
transporter activity
7.0E-03 ± 7.9E-04 5.0E-03 ± 4.9E-04 0.71 0.04
Itrp2 Calcium Ion transmembrane
transporter activity





2.6E-02 ± 2.4E-03 1.7E-02 ± 1.0E-03 0.68 0.01
Camk2g Calmodulin-dependent
kinase activity
2.6E-02 ± 1.8E-03 2.0E-02 ± 3.5E-04 0.79 0.02
Cdh2 Calcium ion binding activity 6.9E-02 ± 1.2E-02 3.2E-02 ± 2.5E-03 0.46 0.01
Kinase signaling Map2k1 MAP kinase activity 1.2E-01 ± 1.0E-02 9.2E-02 ± 4.2E-03 0.73 0.02
Mapk3 MAP kinase activity 6.6E-02 ± 3.9E-03 5.4E-02 ± 2.1E-03 0.81 0.03
Raf1 MAP kinase kinase activity 2.0E-02 ± 7.0E-04 1.6E-02 ± 1.0E-03 0.82 0.03
Prkacb Protein kinase A activity 1.9E-02 ± 1.3E-03 1.5E-02 ± 7.5E-04 0.79 0.04
Akt1 Akt kinase activity 4.2E-02 ± 2.6E-03 3.4E-02 ± 1.6E-03 0.80 0.03
JNK1 C-Jun N-terminal protein
kinase
1.3E-01 ± 3.4E-03 1.9E-01 ± 4.3E-03 1.46 0.02
Il-6 Cytokine activity 1.5E-04 ± 1.5E-05 7.4E-05 ± 9.8E-06 0.48 0.002
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Nicotine alters the synaptic plasticity gene expression in
the cortico-limbic circuits of HIV-1Tg rats
Next, we wanted to determine how nicotine impacts the
expression of genes involved in synaptic plasticity in HIV-
1Tg rats. We found that nicotine significantly altered the
expression of 22, 15, and 11 genes, respectively, in the
hippocampus, PFC, and amygdala (Table 2). A gene ontol-
ogy (GO) analysis of these genes showed that those signifi-
cantly altered by nicotine can be classified into eight, five,
and six signaling pathways in the hippocampus, PFC, and
amygdala, respectively.
Chronic nicotine treatment significantly decreased the
expression of Plcb4, Itpr1, and Itpr3, by 16 %–68 %, in
the hippocampus, of Plcb3 and Itpr3, by18 %–35 %, in the
PFC, and of Plcb4, by 36 % in the amygdala (Fig. 4 and
Additional file 2: Figure S1a). In the Ca+2/calmodulin-
dependent kinase signaling pathway, nicotine signifi-
cantly downregulated the expression of Camk4 and
Camk2g, by 20 %, in the hippocampus but upregulated
the expression of Camk2b, Camk4, Cancna1i, and
Calm3, by 14 %–82 %, in the PFC and of Cacna1g,
Camk2a, and Camk4, by 59 %–72 %, in the amygdala.
In Ras/MEK/ERK signaling pathway, nicotine signifi-
cantly upregulated the expression of Mapk3, Mapk1,
Map2k1, and Kras, by 22 %–67 %, in the hippocampus
and downregulated the expression of Map2k2, Map2k1,
Mapk3, and Braf, by 14 %–33 %, in the PFC and of
Kras, by 23 %, in the amygdala (Table 2).
Consistent with the increased expression of hippocam-
pal MAPK genes, expression of Creb and its cofactors was
changed in nicotine-treated HIV-1Tg rats, with 34 %–
45 % upregulation of Creb1 and Cebpb in the hippocam-
pus, 17 %–28 % downregulation of Cebpb and Creb2 in
the PFC, and 34 %–82 % upregulation of Cebpb and its
target MMP-9 in the amygdala (Table 2; Fig. 4a and b).
Further, chronic nicotine treatment reversed the effect of
viral proteins on the expression of Creb2, which was de-
creased by 35 % in the hippocampus of HIV-1Tg rats.
Nicotine displays distinct effects on synaptic plasticity
gene expression in F344 rats
The same set of genes was analyzed in the hippocampus,
PFC, and amygdala of F344 rats in order to determine
whether nicotine had the same effects on expression of
the genes related to synaptic plasticity under normal
physiological condition. Among the 80 genes examined,
we found that 14 in the hippocampus, 18 in PFC, and
12 in the amygdala, respectively, were differentially
expressed in the nicotine-treated and saline control
groups (Table 3). The GO analysis showed that nicotine
altered four, six, and four signaling pathways in the
hippocampus, PFC, and amygdala, respectively (Table 3).
Table 1 HIV-1 viral proteins induced significant alterations in the expression of synaptic plasticity genes. A total of 80 synaptic
plasticity genes were analyzed using a qRT-PCR-array analysis. Among them, 50 showed significant strain-specific expression (p < 0.05




Ccl2 Chemokine activity 2.0E-04 ± 2.4E-05 1.2E-04 ± 1.2E-05 0.61 0.02
Gabra5 GABA-A receptor activity 4.3E-02 ± 2.1E-03 3.3E-02 ± 2.5E-03 0.77 0.02











2.7E-01 ± 2.4E-03 1.7E-02 ± 5.0E-04 0.63 0.006
Calm2 Calcium ion binding 1.0 ± 7.5E-02 7.4E-01 ± 2.8E-02 0.71 0.01
Kinase signaling Mapk1 MAP kinase activity 2.7E-01 ± 2.2E-02 1.7E-01 ± 1.0E-03 0.61 0.02
Mapk3 MAP kinase activity 9.3E-02 ± 9.4E-03 6.2E-02 ± 2.9E-03 0.67 0.01
Raf1 MAP kinase kinase
kinase activity
2.5E-02 ± 1.5E-03 1.7E-02 ± 8.6E-04 0.69 0.02
Immediate early gene response Ntrk2 Growth factor activity 4.3E-03 ± 5.7E-04 2.5E-03 ± 2.1E-04 0.57 0.01
Junb Transcription factor
activity





4.1E-02 ± 3.5E-3 2.6E-02 ± 2.7E-03 0.63 0.02
Adam10 Metallopeptidase activity 2.6E-02 ± 1.6E-03 1.9E-02 ± 2.0E-03 0.74 0.04
Gria1 Ionotropic glutamate
receptor activity (AMPA)
1.3E-01 ± 3.5E-03 1.0E-01 ± 5.3E-03 0.83 0.02
Dlg4 Scaffold protein binding 2.5E-01 ± 2.9E-01 1.2E-01 ± 6.4E-03 0.46 0.003
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C) Amygdala
A) Hippocampus B) Prefrontal Cortex
Down regulated (FC < 0.90)
Down regulated (FC < 0.90, P < 0.05)
Up regulated (FC > 1.1)
Up regulated (FC > 1.1,P < 0.05)
No regulation or did not include the assay
Fig. 3 Effect of HIV-1 proteins on expression of genes in signaling cascades of synaptic plasticity formation in the hippocampus (a), prefrontal cortex
(b), and amygdala (c). Genes involved in calcium signaling and its downstream targets were upregulated in the hippocampus but downregulated in
the PFC and amygdala of HIV-1Tg rats compared with F344 control rats. The signaling cascades were drawn by IPA
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Table 2 Nicotine-induced alterations in expression of synaptic plasticity genes in the hippocampus, PFC, and amygdala of the HIV-1Tg
rats. Genes exhibited significant alterations in the brain following chronic nicotine treatment in HIV-1Tg rats (p < 0.05 and fold ratio
>20 %). Differential effects of nicotine on the gene expression determined by comparing the HIV-1Tg nicotine-treated group with HIV-1Tg
saline group (Student’s t-test with Bonferroni correction)











Grin2a Ionotropic glutamate receptor 1.0E-01 ± 3.4E-03 9.1E-2 ± 4.9E-03 0.86 0.04





3.9E-02 ± 1.7E-03 3.2E-2 ± 1.9E-03 0.80 0.02
Camk2g Calmodulin-dependent
protein kinase activity
2.5E-02 ± 5.8E-04 2.0E-02 ± 3.6E-04 0.80 0.03
PLC/IP3-mediated calcium signaling Plcb4 Phospholipase C activity 3.9E-04 ± 3.8E-04 2.1E-04- ± 3.8E-03 0.52 0.007
Itpr3 Calcium ion transmembrane
transporter activity
1.3E-03 ± 1.5E-04 8.9E-04 ± 9.0E-05 0.64 0.03
Itpr1 Calcium ion transmembrane
transporter activity
7.2E-02 ± 4.2E-03 6.0E-02 ± 1.5E-03 0.84 0.03
CREB signaling Creb-2 (Atf4) Transcription factor activity 1.1E-02 ± 4.4E-04 8.3E-03 ± 4.2E-04 0.65 0.001
Creb-1 Transcription factor activity 2.3E-02 ± 5.0E-04 3.4E-02 ± 1.8E-03 1.45 0.02
Cbp Transcription factor activity 3.3E-04 ± 2.5E-05 4.4E-04 ± 2.7E-05 1.34 0.01
Kinase signaling Jnk1 C-Jun N-terminal protein kinase 1.2E-02 ± 5.2E-04 1.0E-02 ± 4.7E-04 0.85 0.04
Mapk3 MAP kinase activity 7.2E-02 ± 6.5E-03 8.8E-02 ± 4.8E-03 1.22 0.03
Adcy1 Adenylate cyclase activity 2.5E-01 ± 1.4E-02 3.2E-01 ± 7.0E-03 1.28 0.004
Mapk1 MAP kinase activity 1.8E-01 ± 2.3E-02 2.4E-01 ± 4.2E-03 1.33 0.04
Map2k1 MAP kinase activity 1.6E-01 ± 7.8E-03 2.2E-01 ± 7.3E-03 1.37 0.005
Prkacb Protein kinase A activity 9.5E-02 ± 2.0E-03 1.4E-01 ± 4.2E-03 1.53 0.001
Kras GTPase activity 3.3E-02 ± 2.8E-03 5.3E-02 ± 3.2E-03 1.62 0.002
Immediate early gene
response
Nurr Transcription factor activity 6.6E-03 ± 4.6E-04 8.2E-03 ± 5.6E-04 1.25 0.02
Postsynaptic organization of synapse Synpo Actin binding 4.9E-02 ± 2.5E-03 5.8E-02 ± 9.9E-04 1.14 0.04
Gria2 Ionotropic glutamate
receptor activity (AMPA)
1.6E-01 ± 2.1E-01 2.4E-01 ± 2.0E-02 1.55 0.03
Inflammation-mediated
neurodegenerative signaling




Grin2a Ionotropic glutamate receptor 8.8E-02 ± 9.9E-03 5.1E-02 ± 2.9E-04 0.58 0.01





0.1.7E-01 ± 1.0E-02 2.9E-01 ± 2.3E-03 1.67 0.004
Camk4 Calmodulin-dependent
protein kinase activity
3.1E-02 ± 2.0E-03 5.3E-02 ± 9.3E-04 1.69 0.001
Cacna1i Voltage–gated calcium
channel activity
1.7E-02 ± 1.0E-03 3.2E-02 ± 1.7E-03 1.82 0.003
Calm3 Calcium ion binding 6.0E-01 ± 1.1E-02 7.2E-01 ± 2.7E-02 1.14 0.01
PLC/IP3-mediated calcium signaling Plcb3 Phospholipase C activity 2.2E-03 ± 2.4E-04 1.4E-03 ± 1.2E-04 0.65 0.01
Itpr3 Calcium ion transmembrane
transporter activity
4.5E-03 ± 2.5E-04 3.7E-03 ± 2.1E-04 0.82 0.02
Kinase signaling Map2k2 MAP kinase activity 1.3E-03 ± 7.5E-05 9.3E-04 ± 1.4E-05 0.67 0.005
Map2k1 MAP kinase activity 9.4E-02 ± 5.2E-03 6.5E-01 ± 3.2E-03 0.69 0.002
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The genes involved in PLC/IP3-mediated calcium sig-
naling were significantly downregulated by nicotine in
the three brain regions of F344 rats (P = 0.01–0.04)
(Table 3). However, nicotine showed bidirectional effects
on the expression of genes involved in VDCC-mediated
calcium signaling and the Ca+2/calmodulin-dependent
kinase signaling pathway, with 46 %–57 % upregulation
of Camk4 and Cacnali expression in the hippocampus,
20 %–25 % upregulation of Calm1 and Camk2g expres-
sion in the amygdala, and 56 %–73 % downregulation of
Camk2b, Camk4, Calm2, and Cacna1g expression in the
PFC (Fig. 5 and Additional file 2: Figure S1b). The ex-
pression of genes involved in the Map kinase and AC/
PKA signaling pathways was also significantly altered by
nicotine in F344 rats. In the Raf/MEK/ERK signaling
pathway, nicotine significantly downregulated the ex-
pression of Raf1, Mapk1, and Map2k2, by 25 %–73 %, in
the hippocampus, of Raf1 and Mapk3, by 72 % and
74 %, respectively, in the PFC, and of Raf1, by 72 %, and
Mapk1, by 55 %, in the amygdala. In the AC/PKA signal-
ing, nicotine significantly decreased the expression of
Adcy1, by 22 %, and Prkacb, by 80 %, in the hippocampus
but increased the expression of Adcy1 by 26 % and of
Prkacb by 15 % in the PFC (Table 3). We also observed
nicotine-induced brain region-specific expression alter-
ations in the immediate early gene response. For example,
nicotine significantly upregulated expression of Arc and
Mmp-9 in the hippocampus and of Ngf and Synpo in
the PFC but downregulated the expression of transcrip-
tion factors Fos-b, Fos, Jun-b, and Egr1 and their down-
stream targets BDNF and Ntrk2 in the amygdala
(Table 3 and Fig. 5b).
Discussion
The current study provides detailed information on the ef-
fects of HIV-1 proteins and nicotine on expression of
synaptic plasticity genes in the hippocampal–PFC–
amygdala-dependent learning and memory mechanisms.
The principal findings of this study are: (1) HIV-1 proteins
impaired the hippocampal–PFC-dependent spatial work-
ing and hippocampal–amygdala-dependent contextual
fear memory in HIV-1Tg rats (see Figs. 1 and 2); (2)
the upstream regulators and downstream targets of
intracellular calcium signaling were altered by HIV-1
proteins in a brain region-specific manner (see Fig. 3
and Table 1); (3) chronic nicotine treatment improved
the spatial working and contextual fear memory
performance in HIV-1Tg rats (Figs. 1 and 2) and at-
tenuated the effect of viral proteins on synaptic plas-
ticity formation in a brain region-specific manner (see
Fig. 4 and Table 2); and (4) the effect of nicotine on
the gene expression of synaptic plasticity and context-
ual fear memory formation differed significantly be-
tween the HIV-1Tg and F344 control rats. Nicotine
Table 2 Nicotine-induced alterations in expression of synaptic plasticity genes in the hippocampus, PFC, and amygdala of the HIV-1Tg
rats. Genes exhibited significant alterations in the brain following chronic nicotine treatment in HIV-1Tg rats (p < 0.05 and fold ratio
>20 %). Differential effects of nicotine on the gene expression determined by comparing the HIV-1Tg nicotine-treated group with HIV-1Tg
saline group (Student’s t-test with Bonferroni correction) (Continued)
Braf MAP kinase kinase activity 3.1E-01 ± 1.0E-03 2.3E-02 ± 1.1E-03 0.75 0.001
Mapk3 MAP kinase activity 5.4E-02 ± 2.1E-03 4.7E-02 ± 1.1E-03 0.86 0.04
Akt1 Akt kinase activity 3.4E-02 ± 1.6E-03 5.2E-02 ± 5.2E-03 1.55 0.04
CREB signaling Crem Transcription factor activity 5.3E-03 ± 2.4E-04 3.8E-03 ± 4.1E-04 0.72 0.04




Grin2d Ionotropic glutamate receptor 1.9E-02 ± 1.9E-03 1.4E-02 ± 1.0E-03 0.76 0.04





1.7E-02 ± 5.0E-04 2.7E-02 ± 2.4E-03 1.59 0.006
Camk2a Calmodulin-dependent
protein kinase activity
1.4E-01 ± 3.6E-01 2.4E-01 ± 1.7E-01 1.66 0.001
Camk4 Calmodulin-dependent
protein kinase activity
1.5E-02 ± 1.0E-03 2.6E-03 ± 3.4E-03 1.72 0.02
PLC/IP3-mediated calcium signaling Plcb4 Phospholipase C activity 2.3E-02 ± 2.3E-03 1.5E-02 ± 2.7E-03 0.64 0.04
Calm2 Calcium ion binding 7.4E-01 ± 2.8E-02 5.9E-01 ± 1.9E-02 0.80 0.02
Kinase signaling Kras GTPase activity 4.1E-02 ± 2.8E-03 3.2E-03 ± 2.5E-03 0.77 0.04
Prkacb Protein kinase A activity 1.5E-01 ± 8.3E-03 2.4E-01 ± 1.3E-03 1.55 0.001
CREB signaling Cbp Transcription factor activity 3.3E-04 ± 2.5E-05 4.4E-04 ± 2.7E-05 1.34 0.01
Immediate early gene response Mmp-9 Metallopeptidase activity 7.1E-05 ± 1.2E-05 1.3E-04 ± 2.0E-05 1.82 0.03
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impaired the contextual learning and related gene ex-
pression in the amygdala of the F344 rats (Fig. 2;
Table 3). Together, these findings indicate that nico-
tine as a cholinergic channel modulator can attenuate
HIV-1 effects on synaptic plasticity and memory for-
mation, and the effect of hippocampal–amygdala-
dependent contextual fear memory differed in the
healthy (i.e., F344 rats) and disease (i.e., HIV-1Tg
rats) states.
HIV-1 proteins disturb synaptic plasticity formation in the
hippocampus–PFC–amygdala circuit and impair the
working and contextual memory in HIV-1Tg rats
Typically, HAND occurs in the early stages of HIV-1 in-
fection and causes slow performance in the encoding and
retrieval of spatial and contextual related information [5].
The HIV-1Tg rat expresses seven of the nine HIV genes
and shows neurological and cognitive complications simi-
lar to those observed in HAND patients [32–34]. The
non-infective HIV-1Tg rat offers a valid model for investi-
gating the neuropathological aspects of memory impair-
ment in HAND patients. Specifically, in this study, we
showed that viral proteins induced a deficit in both spatial
working and contextual memory performance in these an-
imals. As shown in Figures 1a and 2, HIV-1Tg rats exhib-
ited low spontaneous alteration behavior in the Y-maze
and short latency in entering the dark box during the re-
tention trials of the one-step-through passive avoidance
test compared with the F344 control rats. Given that the
HIV-1Tg rats show strong neuropathological similarities
to HIV-1-infected patients with concomitant expression
of multiple HIV genes, the observed memory deficits in
HIV-1Tg rats are most likely the result of the neurodegen-
erative effects of multiple HIV-1 proteins within the
neural circuits of learning and memory.
Glutamate-mediated excitotoxicity has been consid-
ered a central pathological mechanism for the effects of
HIV-1 proteins on the neurodegenerative process in the
brain [16]. These proteins lead to glutamate-induced de-
regulation of calcium homeostasis by over-activating the
glutamate receptors and facilitating neurodegeneration
in the brain [17, 18, 35, 36]. When an excessive amount
of glutamate is released from the microglia and pre-
synaptic neurons during the neurodegeneration, the cal-
cium conductance of NMDA receptors is inhibited by
intracellular calcium through calcium sensitive proteins
A) Hippocampus B) Amygdala
Down regulated (FC < 0.90)
Down regulated (FC < 0.90, P < 0.05)
Up regulated (FC > 1.1)
Up regulated (FC > 1.1, P < 0.05)
No regulation or did not include the assay
Fig. 4 Synergistic effects of HIV-1 proteins and nicotine on the expression of genes in the signaling cascades of synaptic formation in the
hippocampus (a) and amygdala (a). Chronic nicotine treatment attenuated the HIV-1 protein effect on the expression of genes involved in
calcium signaling cascades. Genes encoding the upstream regulators and downstream targets of calcium signaling cascades were
downregulated by nicotine in the hippocampus but were upregulated by nicotine in the amygdala compared with the HIV-1Tg saline-treated
group. Signaling cascades were drawn by IPA
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Table 3 Effect of nicotine on expression of genes involved in synaptic plasticity in the hippocampus, PFC, and amygdala of F344
rats. Significant expression alterations were determined by comparing the F344 nicotine-treated group with the F344 saline-treated
















3.3E-02 ± 1.1E-03 5.2E-02 ± 9.4E-04 1.57 0.007
Cacna1i Voltage–gated calcium channel
activity
2.0E-03 ± 3.6E-04 2.9E-03 ± 1.1E-04 1.46 0.03
PLC/IP3-mediated calcium signaling Plcb4 Phospholipase C activity 2.4E-02 ± 2.2E-04 1.5E-02 ± 2.2E-03 0.66 0.02
Kinase signaling Hras GTPase activity 8.7E-06 ± 2.2E-06 4.1E-06 ± 1.7E-05 0.47 0.04
Prkacb Protein kinase A activity 1.9E-02 ± 1.3E-03 1.5E-02 ± 1.6E-03 0.82 0.02
Adcy1 Adenylate cyclase activity 3.3E-01 ± 2.1E-02 2.6E-01 ± 2.1E-02 0.78 0.006
Mapk1 MAP kinase activity 4.3E-01 ± 2.1E-02 5.4E-01 ± 4.3E-03 1.25 0.01
Raf1 MAP kinase kinase activity 2.0E-02 ± 7.0E-04 3.0E-02 ± 2.1E-03 1.52 0.01
Map2k2 MAP kinase activity 2.3E-03 ± 1.7E-04 4.0E-03 ± 2.4E-04 1.73 0.001
Immediate early response gene Ntrk2 Neurotrophin receptor activity 2.0E-03 ± 3.0E-04 1.1E-03 ± 5.1E-05 0.53 0.04
Egr1 Transcription factor activity 9.4E-02 ± 9.6E-03 5.3E-02 ± 5.7E-03 0.55 0.03
Jun-b Transcription factor activity 1.5E-02 ± 2.2E-03 9.0E-03 ± 1.3E-03 0.57 0.02
Arc Activity-regulated cytoskeleton-
associated protein
1.2E-02 ± 2.0E-03 7.9E-03 ± 8.0E-04 0.63 0.03




Grin2c Ionotropic glutamate receptor 1.1E-02 ± 1.1E-03 8.5E-03 ± 5.2E-04 0.72 0.04





1.7E-01 ± 1.0E-02 2.9E-01 ± 2.3E-03 1.67 0.004
Cacna1g Voltage–gated calcium channel
activity
2.6E-02 ± 2.4E-03 4.0E-02 ± 2.5E-03 1.56 0.004
Camk4 Calmodulin-dependent protein
kinase activity
3.3E-02 ± 2.1E-03 5.3E-02 ± 3.3E-03 1.60 0.002
Calm2 Calcium ion binding 4.4E-01 ± 6.0E-02 7.8E-01 ± 3.9E-02 1.73 0.001
PLC/IP3-mediated calcium
signaling
Itpr2 Calcium ion transmembrane
transporter activity
7.0E-03 ± 7.9E-04 4.6E-03 ± 3.3E-04 0.66 0.04
Plcb3 Phospholipase C activity 3.0E-03 ± 2.4E-04 2.0E-03 ± 2.6E-04 0.68 0.03
Itpr1 Calcium ion transmembrane
transporter activity
7.0E-03 ± 7.9E-04 5.1E-01 ± 6.9E-04 0.73 0.01
Kinase signaling Raf1 MAP kinase kinase activity 2.0E-02 ± 7.0E-04 1.4E-02 ± 1.8E-03 0.72 0.03
Mapk3 MAP kinase activity 6.6E-02 ± 3.9E-03 4.9E-02 ± 1.1E-03 0.74 0.006
Prkacb Protein kinase A activity 1.9E-02 ± 1.3E-03 2.3E-02 ± 4.7E-03 1.15 0.01
Akt1 Akt kinase activity 4.2E-02 ± 2.6E-03 5.0E-02 ± 3.1E-03 1.26 0.02
Adcy8 Adenylate cyclase activity 3.9E-03 ± 4.2E-04 5.1E-03 ± 2.4E-04 1.31 0.02
Immediate early response gene Synpo Actin binding 3.4E-02 ± 2.6E-03 4.4E-02 ± 2.8E-03 1.27 0.04
Ngf Growth factor activity 1.5E-03 ± 1.6E-04 1.9E-03 ± 7.2E-05 1.29 0.03
Inflammation-mediated
neurodegenerative signaling
Il-6 Cytokine activity 1.5E-4 ± 1.5E-05 7.0E-05 ± 7.8E-06 0.45 0.001
Tnf Cytokine activity 4.2E-04 ± 1.1E-04 3.0E-04 ± 2.8E-05 0.70 0.04
Amygdala
Calm1 Calcium ion binding 1.2 ± 9.0E-02 9.2E-01 ± 7.8E-02 0.75 0.04
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Table 3 Effect of nicotine on expression of genes involved in synaptic plasticity in the hippocampus, PFC, and amygdala of F344
rats. Significant expression alterations were determined by comparing the F344 nicotine-treated group with the F344 saline-treated





3.2E-2 ± 2.4E-03 2.5E-02 ± 1.6E-03 0.80 0.04
PLC/IP3-mediated calcium signaling Itpr2 Calcium ion transmembrane
transporter activity
6.8E-03 ± 4.2E-04 5.5E-03 ± 1.0E-04 0.80 0.02
Itpr3 Calcium ion transmembrane
transporter activity
3.6E-03 ± 3.4E-04 3.0E-03 ± 7.7E-05 0.82 0.03
Kinase signaling Mapk1 MAP kinase activity 2.7E-01 ± 2.2E-02 1.5E-01 ± 2.0E-01 0.55 0.007
Raf1 MAP kinase kinase activity 2.5E-02 ± 1.5E-03 1.8E-02 ± 2.0E-03 0.72 0.02
Immediate early response gene Fos-b Transcription factor activity 1.0E-02 ± 3.2E-03 3.8E-03 ± 9.7E-04 0.38 0.03
Junb Transcription factor activity 1.5E-02 ± 2.2E-0 8.0E-03 ± 1.4E-03 0.51 0.02
Egr1 Transcription factor binding activity 9.4E-02 ± 9.7E-03 5.8E-02 ± 3.8E-03 0.61 0.01
Ntrk2 Neurotrophin receptor activity 4.3E-03 ± 5.7E-04 2.6E-03 ± 1.9E-04 0.61 0.02
Bdnf Growth factor activity 9.2E-05 ± 5.3E-06 5.8E-05 ± 1.6E-05 0.63 0.03
Fos Transcription factor activity 3.0E-03 ± 5.0E-04 1.9E-03 ± 2.0E-04 0.63 0.04
A) Hippocampus B) Amygdala
Down regulated (FC < 0.90)
Down regulated (FC < 0.90, P < 0.05)
Up regulated (FC > 1.1)
Up regulated (FC > 1.1, P < 0.05)
No regulation or did not include the assay
Fig. 5 Regulation of synaptic plasticity gene expression by nicotine in the hippocampus (a) and amygdala (b) of F344 rats. Moderate chronic
dose of nicotine increased expression of genes in the Ca+2/calmodulin-dependent kinase-IV signaling and Raf/Mek/Erk signaling pathways in the
hippocampus. However, the same dose of nicotine downregulated the majority of synaptic plasticity genes in the amygdala compared with the
F344 saline-treated group. Signaling cascades were drawn by IPA
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[37]. The calcium-induced NMDA receptor inactivation
serves as a negative feedback mechanism and results in
downregulation of NMDA receptors [38–40]. Here, we
demonstrated that HIV-1Tg rats showed significant
downregulation of NMDA receptor subunits in the
hippocampus, PFC and amygdala (Fig. 1). This result
suggests the activation of the negative feedback loop,
which could operate as a physiological homeostatic
mechanism to limit the level of neurotoxicity caused by
viral proteins. However, this type of protection may also
limit the level of neuronal activity in HIV-1Tg rats that
may contribute to spatial and contextual memory deficit.
Further, our gene expression data showed the selective
effects of viral proteins on the expression of genes in the
intracellular calcium signaling pathways. As shown
Figure 3a, viral proteins significantly upregulated the ex-
pression of genes involved in mGluR5-mediated calcium
signaling but downregulated the expression of immedi-
ate early genes (IEGs) in the hippocampus. These results
support previous studies, which showed that low expres-
sion of IEG mRNAs was associated with mGluR-
dependent long-term depression (LTD) formation in the
hippocampus [41–43]. However, HIV-1 proteins de-
creased calcium signaling in the PFC and amygdala by
downregulating genes in the VDCC- and PLC/IP3-medi-
ated calcium signaling pathways (Fig. 3b, c). Consider-
able evidence demonstrates that dysfunction in VDCC
and IP3 receptor activity plays a central role in synaptic
loss and memory impairment during neurodegeneration
in the brain. In particular, reduction in calcium signaling
inhibits onset of LTP and long-term memory acquisition
through deactivation of calcium-sensitive Ras/ERK and
CAMK signaling pathways [44, 45]. We confirmed the
aforementioned findings in cognitively impaired HIV-
1Tg rats by showing the low expression of VDCC and
IP3 receptor genes with significant downregulation in
the calcium-sensitive protein kinase signaling pathways
in both the PFC and the amygdala (see Table 1).
The results presented here clearly show that HIV-1
proteins display a brain region-specific effect on calcium
signaling, which may be considered an important factor
causing synaptic plasticity dysfunction and memory im-
pairment in HIV-1Tg rats. One possible explanation for
this effect is that HIV-1 proteins enhance hippocampal
LTD induction by overactivating mGluRs-PLC/IP3- me-
diated calcium signaling through excessive release of
glutamate from the microglia cells. The viral proteins
mediate this deregulation of calcium signaling and may
facilitate the synaptic loss and reduce the hippocampal
synaptic projections to the PFC and amygdala. Low hip-
pocampal presynaptic stimulation of the PFC and amyg-
dala circuits could reduce the LTP induction that is
mediated by calcium entry through VDCC in the neu-
rons of the PFC and amygdala. Further, in support of the
link between hippocampal LTD and LTP formation in
the PFC and amygdala of HIV-1Tg rats, blocking LTP in-
duction in the hippocampus inhibits LTP formation in
the medial PFC-basolateral amygdala [46]. These alter-
ations are associated with memory impairment during
brain neurodegeneration [47, 48].
Chronic nicotine treatment attenuates the effects of HIV-1
proteins on synaptic plasticity and enhances working and
contextual memory in HIV-1Tg rats
Nicotine as well as other nicotinic receptor agonists
show neuroprotective effects against glutamate-mediated
neurotoxicity and enhance cognitive performance in a
variety of neurodegenerative disorders [25, 49, 50]. As
such, this cognitive-enhancing effect of nicotine is de-
fined as one of the main reasons that hinder efforts to
quit smoking in HIV-1-infected patients [7]. Nicotine
received through cigarette smoking in these patients
preassumely increases the risk for HIV-1 infection re-
lated disease progression and mortality [7]. Therefore,
determination of the molecular mechanisms underlying
cognitive-enhancing and neuroprotective effects of nico-
tine in this particular population will provide new in-
sights into potential drug treatment.
Nicotine can affect glutamatergic neurotransmission
directly through nAChRs and indirectly through VDCC
and IP3 receptors and modulate calcium signaling in
glutamatergic neurons [51, 52]. However, the regulatory
effects of nicotine on these calcium signaling pathways
depend on the distribution of nAChRs and baseline
intracellular calcium concentrations among the brain
regions during neurodegeneration. Neuronal nicotinic
acetylcholine receptors can contribute to modify the
function of ionotropic glutamate receptors. Stimulation
of α7 and β2 nicotinic acetylcholine receptors by cho-
linergic agonists decreases the surface expression of the
NMDA receptor subunits during the glutamate toxicity.
Shen et al. [53] reported that pre-treatment of nicotine
abolished the glutamate-induced calcium influx by modu-
lating surface expression of NMDA receptors through kin-
ase signaling. Our results showed that chronic nicotine
treatment significantly decreased expression of NMDA re-
ceptor subunits in the hippocampus, PFC, and amygdala
of HIV-1Tg rats, as compared with their saline-treated
counterparts (Fig. 4 and Additional file 2: Figure S1a). This
suggests that nicotine may engage with negative feedback
mechanisms in response to NMDA receptor activity-
dependent calcium influx and contribute to limit the levels
of neurotoxicity within neural circuits of learning and
memory.
Our findings also showed that chronic nicotine treat-
ment attenuated the effects of HIV-1 proteins on spatial
working and contextual memory formation by selectively
modulating the calcium-signaling pathways in the
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hippocampus, PFC, and amygdala. As shown in Figure 3
and Additional file 2: Figure S1a, nicotine significantly de-
creased the expression of IP3 receptor genes in the hippo-
campus and increased the expression of VDCC-mediated
calcium signaling genes in the PFC and amygdala. Fur-
thermore, we provide evidence for the nicotinic regulation
of downstream protein kinase signaling pathways in the
hippocampus, PFC, and amygdala of HIV-1Tg rats. Nico-
tine increased the expression of genes involved in MAPK
and Creb signaling in the hippocampus and upregulated
expression of CAMKs in the PFC and amygdala of HIV-
1Tg rats (Table 2). These results indicate that nicotine
shifted the formation of LTD into LTP induction in the
hippocampus and promoted LTP expression in the PFC
and amygdala, resulting in enhanced memory formation
in HIV-1Tg rats. In contrast with our findings, Atluri and
colleagues have demonstrated the negative effects of nico-
tine on the expression of synaptic plasticity gene expres-
sion and spine density in HIV-1 infected SK-N-MC cells
[54]. Given the differences in the administration route of
nicotine and different models of infection, an animal
model of HIV-1 infection has more capability of assessing
the mechanism of action of nicotine by providing detailed
information in cognitively impaired HIV-1-infected pa-
tients. In fact, the observed positive effects of nicotine on
the synaptic plasticity formation within the hippocampus,
PFC, and amygdala circuits might be a secondary outcome
caused by its anti-inflammatory effects in the central ner-
vous system (CNS). Nicotine has been proved effective
in suppressing inflammation in patients with Alzheimer
and Parkinson diseases by modulating the cholinergic
anti-inflammatory pathway, which contributes to cogni-
tive enhancement in these patients. Recently, Depboylu
et al. [19] reported that chronic inflammation induced
by HIV-1 proteins reduced cholinergic transmission in
the basal forebrain of rhesus macaques, suggested dys-
function of cholinergic anti-inflammatory pathway in
the central nervous system. In this respect, the actions
of nicotine in the anti-inflammatory system should be
considered a factor in the findings from the present
study that nicotine might also have an effect on
microglia-dependent glutamate release, which could
contribute to its modulatory effect in the neural circuits
of learning and memory in HIV-1Tg rats.
Nicotine shows differential effects on contextual memory
formation in the health and disease states
In addition to the effects of nicotine on synaptic plasti-
city formation in HIV-1Tg rats, we analyzed the effects
of nicotine in F344 rats to determine whether the drug
exerts differential modulator effects on the synaptic plas-
ticity and memory formation in health and disease
states. When F344 rats were subjected to chronic nico-
tine treatment, the drug had different effects on spatial
working memory and contextual fear memory. The drug
enhanced the working memory performance in the Y-
maze, whereas it impaired the contextual fear memory
in the passive avoidance test (Figs. 1 and 2). This obser-
vation is consistent with previous reports [55, 56], where
chronic nicotine treatment impaired short- and long-
term formation of contextual fear memory. Here, we
also showed that nicotine modulated gene expression in
the hippocampus, PFC, and amygdala that was different
from the effects in HIV-1Tg rats. Further, chronic nico-
tine treatment increased the expression of genes in the
intracellular calcium signaling, Ca+2/calmodulin-
dependent kinase, and IEG in the hippocampus and
PFC, whereas it downregulated the majority of synaptic
plasticity-related genes in the amygdala of F344 rats
(Table 3). These results indicate that nicotine had posi-
tive effects on the hippocampus–PFC circuit-dependent
spatial working memory but showed negative effects on
the formation of long-term episodic memory by de-
creasing gene expression in the amygdala, which is a
predominant neural component in the neural circuit of
contextual fear memory formation.
Conclusion
The prevalence of cigarette smoking among HIV-1 in-
fected patients is high. It has been hypothesized that pa-
tients with HIV-1 infection use nicotine to compensate
for HIV-1-related complications, including cognitive def-
icit. Our results indicate that HIV-1 proteins significantly
disrupt synaptic plasticity formation by altering the ex-
pression of genes involved in intracellular calcium signal-
ing pathways in a brain region-specific manner, which
results in the deficit in spatial and contextual fear memory
observed in HIV-1Tg rats. On the other hand, the effect of
HIV-1 proteins is attenuated by chronic nicotine treat-
ment in HIV-1Tg rats. Interestingly, the effect of nicotine
on spatial and contextual memory performance appears to
be different in the healthy and disease states. This may ex-
plain why nicotine shows different effects on the stimula-
tion of neural circuits of learning and memory in these
two states. Together, these results are helpful for elucidat-
ing the molecular mechanisms underlying the cognitive
impairment in HIV-1-infected smokers.
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